161 related articles for article (PubMed ID: 37808997)
21. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
Osunkwo I; Andemariam B; Minniti CP; Inusa BPD; El Rassi F; Francis-Gibson B; Nero A; Trimnell C; Abboud MR; Arlet JB; Colombatti R; de Montalembert M; Jain S; Jastaniah W; Nur E; Pita M; DeBonnett L; Ramscar N; Bailey T; Rajkovic-Hooley O; James J
Am J Hematol; 2021 Apr; 96(4):404-417. PubMed ID: 33264445
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.
Gallagher ME; Chawla A; Brady BL; Badawy SM
J Med Econ; 2022; 25(1):1140-1148. PubMed ID: 36222016
[TBL] [Abstract][Full Text] [Related]
23. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance.
Johnson KM; Jiao B; Ramsey SD; Bender MA; Devine B; Basu A
Blood Adv; 2023 Feb; 7(3):365-374. PubMed ID: 35575558
[TBL] [Abstract][Full Text] [Related]
24. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
[TBL] [Abstract][Full Text] [Related]
25. Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France.
Roche N; Garcia G; de Larrard A; Cancalon C; BĂ©nard S; Perez V; Mahieu A; Vieu L; Demoly P
BMJ Open; 2022 Aug; 12(8):e060160. PubMed ID: 36002203
[TBL] [Abstract][Full Text] [Related]
26. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
[TBL] [Abstract][Full Text] [Related]
27. Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease.
Harris KM; Preiss L; Varughese T; Bauer A; Calhoun CL; Treadwell M; Masese R; Hankins JS; Hussain FA; Glassberg J; Melvin CL; Gibson R; King AA;
JAMA Netw Open; 2023 May; 6(5):e2314070. PubMed ID: 37200033
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
29. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
31. Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy.
De Franceschi L; Castiglioni C; Condorelli C; Valsecchi D; Premoli E; Fiocchi C; Perrone V; Esposti LD; Forni GL; On Behalf Of The GREATalyS Study Group
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614918
[TBL] [Abstract][Full Text] [Related]
32. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Brandow AM; Wandersee NJ; Dasgupta M; Hoffmann RG; Hillery CA; Stucky CL; Panepinto JA
Br J Haematol; 2016 Oct; 175(2):237-245. PubMed ID: 27539682
[TBL] [Abstract][Full Text] [Related]
33. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
34. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
35. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia.
Albohassan H; Ammen M; Alomran AA; Bu Shehab H; Al Sakkak H; Al Bohassan A
Cureus; 2022 Nov; 14(11):e31527. PubMed ID: 36540486
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
37. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.
Drawz P; Ayyappan S; Nouraie M; Saraf S; Gordeuk V; Hostetter T; Gladwin MT; Little J
Clin J Am Soc Nephrol; 2016 Feb; 11(2):207-15. PubMed ID: 26672090
[TBL] [Abstract][Full Text] [Related]
38. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
40. [Digestives diseases associated to sickle cell anemia in Lubumbashi: epidemiological and clinical aspects].
Banza MI; Mulefu JP; Lire LI; N'dwala YTB; Tshiamala IB; Cabala VPK
Pan Afr Med J; 2019; 33():253. PubMed ID: 31692839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]